ArticleBJU international2025
Long-term outcomes of bladder-sparing therapy vs radical cystectomy in BCG-unresponsive non-muscle-invasive bladder cancer.
Article in BJU international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Combination therapy for BCG-unresponsive non-muscle-invasive bladder cancer: biological rationale and ongoing clinical strategies.Nature reviews. Urology · 2026Review
- Beyond the BCG Paradox: Biological Rationale and Clinical Evidence for Combining Intravesical BCG with Immune Checkpoint Inhibitors in High-Risk Non-muscle-Invasive Bladder Cancer.Oncology and therapy · 2026Review
- Gemcitabine-Based Bladder Preservation in BCG-Unresponsive High-Risk NMIBC: Evidence, Limitations, and Clinical Positioning.Biomedicines · 2026Review
- 'BJUI Clinical Dilemma': Recurrent high-grade non-muscle-invasive bladder cancer in 2026.BJU international · 2026Article
- ASO Practice Guidelines Series: Surgical Management of Bladder Cancer Relapse.Annals of surgical oncology · 2026Review
- Advances in the management of localized bladder cancers.Nature reviews. Clinical oncology · 2026Review
- Long-term outcomes of a cascading salvage strategy for high-risk non-muscle-invasive bladder cancer.BJU international · 2026Article
- Modern management of BCG-refractory non-muscle-invasive urothelial carcinoma of the urinary bladder.Urologie (Heidelberg, Germany) · 2026Review
- Cost-effectiveness Analysis of Treatments for Bacillus Calmette-Guérin-unresponsive Carcinoma in Situ of the Bladder.European urology · 2026Article
- Real-world outcomes of bladder-sparing strategies for BCG-unresponsive non-muscle-invasive bladder cancer: a multicenter study.World journal of urology · 2026Article
- Sequential Intravesical Gemcitabine and Docetaxel for Non-Muscle Invasive Bladder Cancer: A Narrative Review Across Risk Groups.Research and reports in urology · 2026Review
- BCG after trimodality therapy: managing non-muscle-invasive recurrence in the irradiated bladder.Frontiers in oncology · 2026Review
- Single-cell RNA sequencing identifies potential critical prognostic biomarkers in bladder carcinoma.Scientific reports · 2025Article
- Outcomes in BCG failure: Outcome from a single centre UK experience.BJUI compass · 2025Article
- Therapeutic Advances in Bladder Preservation for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer.Cancers · 2025Review
- Article
- The role of blue light cystoscopy and additional operative evaluations during first surveillance after induction therapy for high-risk NMIBC.Bladder cancer (Amsterdam, Netherlands)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
24 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo quantify the oncological risks of bladder-sparing therapy (BST) in patients with Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC) compared to upfront radical cystectomy (RC). PATIENTS AND
methodsPre-specified data elements were collected from retrospective cohorts of patients with BCG-unresponsive NMIBC from 10 international sites. After Institutional Review Board approval, patients were included if they had BCG-unresponsive NMIBC meeting United States Food and Drug Administration criteria. Oncological outcomes were collected following upfront RC or BST. BST regimens included re-resection or surveillance only, repeat BCG, intravesical chemotherapy, systemic immunotherapy, and clinical trials.
resultsAmong 578 patients, 28% underwent upfront RC and 72% received BST. The median (interquartile range) follow-up was 50 (20-69) months. There were no statistically significant differences in metastasis-free survival, cancer-specific survival, or overall survival between treatment groups. In the BST group, high-grade recurrence rates were 37% and 52% at 12 and 24 months and progression to MIBC was observed in 7% and 13% at 12 and 24 months, respectively. RC was performed in 31.7% in the BST group and nodal disease was found in 13% compared with 4% in upfront RC (P = 0.030).
conclusionIn a selected cohort of patients, initial BST offers comparable survival outcomes to upfront RC in the intermediate term. Rates of recurrence and progression increase over time especially in patients treated with additional lines of BST.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.